Antimicrobials are the most commonly used drugs. Because of increasing resistance, the effective antimicrobials are becoming limited and this is an important cause of mortality and morbidity, that will become even more significant in the future. Accordingly, antimicrobial stewardship gained importance. Antimicrobial Stewardship (AMS) includes the experience of ESGAP workshops and courses on antibiotic stewardship since 2012. It combines clinical and laboratory information about AMS, with the focus on human medicine. The ESCMID study group on antibiotic policies (ESGAP) is one of the most productive groups in the field. The group organizes courses and workshops. Such a book will be an ideal tool for the participants of the workshop.
With short chapters (around 1500 words) written on different topics the authors insisted on the following points: - hands on, practical approach - tips to increase success - description of the most common mistakes - global picture (out- and inpatient settings, all countries) - short list of 10-20 landmark references
- Focuses on the most recent AMS strategies
- Provides a detailed description of laboratory support
- Offers a balanced synthesis of basic and clinical sciences for each individual case, presenting clinical courses of the cases in parallel with the pathogenesis and detailed microbiological information for each infection
- Describes the prevalence and incidence of the global issues and current therapeutic approaches
- Presents the measures for infection control
Papildus informācija
Provides updated knowledge of bacterial resistance and recent developments in antimicrobial stewardship
Contributors |
|
xi | |
Foreword |
|
xv | |
|
Introduction |
|
xvii | |
|
Introduction |
|
xix | |
|
Introduction |
|
xxi | |
|
Preface |
|
xxiii | |
Acknowledgments |
|
xxv | |
|
Section A The Global Picture of Antimicrobial Use and Resistance |
|
|
|
1 The Global Crisis of Antimicrobial Resistance |
|
|
3 | (10) |
|
|
|
2 Antimicrobial Stewardship: Efficacy and Implementation of Strategies to Address Antimicrobial Overuse and Resistance |
|
|
13 | (16) |
|
|
|
3 Quality Indicators and Quantity Metrics of Antibiotic Use |
|
|
29 | (12) |
|
|
|
|
|
4 Improving Antimicrobial Prescribing: Input from Behavioral Strategies and Quality Improvement Methods |
|
|
41 | (14) |
|
|
|
5 Education of Healthcare Professionals on Responsible Antimicrobial Prescribing |
|
|
55 | (14) |
|
|
|
6 Rapid Diagnostics and Biomarkers for Antimicrobial Stewardship |
|
|
69 | (16) |
|
|
7 Pharmacokinetic and Pharmacodynamic Tools to Increase Efficacy |
|
|
85 | (14) |
|
|
|
|
8 The Use of Computerized Decision Support Systems to Support Antimicrobial Stewardship Programs |
|
|
99 | (16) |
|
|
9 The Role of Microbiology Laboratory in Promoting Antimicrobial Stewardship |
|
|
115 | (14) |
|
|
|
10 The Role of Pharmacists |
|
|
129 | (10) |
|
|
11 The Roles of Nurses in Antimicrobial Stewardship |
|
|
139 | (8) |
|
|
|
12 Antifungal Stewardship |
|
|
147 | (20) |
|
|
|
Section C AMS in Specific Clinical Settings |
|
|
|
13 Optimising Prescribing for Acute Respiratory Tract Infections as an Example for Antimicrobial Stewardship in Primary Care |
|
|
167 | (8) |
|
|
|
|
14 Antimicrobial Stewardship: What to Tell the Patients and the General Public |
|
|
175 | (10) |
|
|
15 Antimicrobial Stewardship in Long-Term Care Facilities |
|
|
185 | (8) |
|
|
16 Antimicrobial Stewardship in ICU |
|
|
193 | (12) |
|
|
|
17 Antimicrobial Stewardship in Hematology Patients |
|
|
205 | (14) |
|
|
18 AMS in an Era of Multidrug-Resistant Bacteria |
|
|
219 | (16) |
|
|
|
|
|
Section D AMS Experiences Around the World |
|
|
|
19.1 AMS Initiatives and Policies: The International Picture |
|
|
235 | (4) |
|
|
|
19.2 Missions and Objectives of EUCIC and ESGAP |
|
|
239 | (4) |
|
|
|
19.3 Antimicrobial Stewardship in Latin America |
|
|
243 | (4) |
|
|
|
|
Cristhian Hernandez-Gomez |
|
|
|
|
19.4 Antimicrobial Stewardship in Australia |
|
|
247 | (4) |
|
|
|
19.5 Antimicrobial Stewardship in Austria |
|
|
251 | (4) |
|
|
19.6 Antimicrobial Stewardship in Belgium |
|
|
255 | (4) |
|
|
|
19.7 Antimicrobial Stewardship in Bulgaria |
|
|
259 | (4) |
|
|
|
19.8 Antimicrobial Stewardship in Croatia |
|
|
263 | (4) |
|
|
|
19.9 Antimicrobial Stewardship in England |
|
|
267 | (4) |
|
|
19.10 Antimicrobial Stewardship in France |
|
|
271 | (4) |
|
|
|
19.11 Antimicrobial Stewardship in Germany |
|
|
275 | (6) |
|
|
|
19.12 Antimicrobial Stewardship in Greece |
|
|
281 | (4) |
|
|
|
19.13 Antimicrobial Stewardship in India |
|
|
285 | (4) |
|
|
19.14 Antimicrobial Stewardship in Israel |
|
|
289 | (4) |
|
|
19.15 Antimicrobial Stewardship in Italy |
|
|
293 | (4) |
|
|
|
19.16 Antimicrobial Stewardship in Japan |
|
|
297 | (2) |
|
|
19.17 Antibiotic Stewardship in the Netherlands |
|
|
299 | (2) |
|
|
|
|
19.18 Antimicrobial Stewardship in Scotland |
|
|
301 | (4) |
|
|
|
19.19 Antimicrobial Stewardship in Slovenia |
|
|
305 | (4) |
|
|
|
19.20 Antimicrobial Stewardship in South Africa |
|
|
309 | (4) |
|
|
19.21 Antimicrobial Stewardship in Argentina |
|
|
313 | (4) |
|
|
19.22 Antimicrobial Stewardship in Spain |
|
|
317 | (4) |
|
|
|
19.23 Antibiotic Stewardship in Sweden |
|
|
321 | (8) |
|
|
|
|
19.24 Antimicrobial Stewardship in Switzerland |
|
|
329 | (2) |
|
|
|
|
19.25 Antimicrobial Stewardship in Turkey |
|
|
331 | (4) |
|
|
|
|
19.26 Antimicrobial Stewardship in the United States |
|
|
335 | (6) |
|
|
|
Section E Research and Perspectives |
|
|
|
20 Methodological Challenges in Evaluating Antimicrobial Stewardship Programs: "Through Measuring to Knowledge" |
|
|
341 | (20) |
|
|
Index |
|
361 | (2) |
List of Abbreviations |
|
363 | |
Céline Pulcini is Full Professor of Infectious Disease in Nancy, France. Her main research interest lies in antimicrobial stewardship and vaccination practices with the aim of preventing the emergence of bacterial resistance to antibiotics.
Professor Pulcini is Secretary of ESGAP, the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Antibiotic Policies. She is or has recently served also as Expert for the National Antibiotic Plan of the French Ministry of Health, the ECDC and the WHO. She is a member of the Executive Committee of the French Infectious Diseases Society (SPILF) and she coordinates the SPILF Antimicrobial Stewardship working group. In addition to this, Professor Pulcini is a partner in the European Innovative Medicines Initiative project DRIVE-AB.
As well as serving as an Associate Editor for the journal Clinical Microbiology and Infection, Professor Pulcini has also authored or co-authored over 130 international publications. She received in 2017 the ESCMID Young Investigator Award. Onder Ergonul, MD, MPH has been a professor of Infectious Diseases and Clinical Microbiology at Koē University, School of Medicine since 2011. He graduated from Hacettepe University School of Medicine in 1989 and completed his residency in 1996 in the Infectious Diseases and Clinical Microbiology department of Ankara University in Ankara, Turkey. He received his Master of Public Health degree from Harvard University School of Public Health in 2003. In 2000-2002, he worked as a research fellow in the Clinical Epidemiology division of the Infectious Diseases Department at the University of Utah, School of Medicine, USA. He is the editor of a book on Crimean-Congo Hemorrhagic Fever (2007, Springer). He received the Public Health Scientific award of Turkish Medical Association in 2007. He has been the president of the Turkish Society of Clinical Microbiology and Infectious Diseases since 2013. He has been the associate editor of Clinical Microbiology and Infection, official journal of the European Society of Clinical Microbiology and Infectious Diseases since 2013. He was elected as the member of Science Academy of Turkey in 2013. Fusun Can, MD Can is an associate professor of medical microbiology at the Koc University School of Medicine. She is specialized in the epidemiology of emerging bacterial pathogens, antibiotic resistance mechanisms and biofilm related infections. She graduated from Hacettepe University School of Medicine in 1989 and completed her residency in 1996 at Ankara University, Department of Microbiology and Clinical Microbiology in Ankara,Turkey. She worked as a research fellow in the Department of Microbiology at the University of Florida School of Medicine, USA. Before joining Koc University, she was the director of the Department of Medical Microbiology at Baskent University, in Ankara. She is responsible for the Microbiology and Biosafety Level III Laboratory at Koc University. Prof. Bojana Beovi, MD, PhD graduated at Medical School University in Ljubljana where she obtained her master degree and PhD. She was further educated in pharmacology at the University of Zagreb, Croatia and at The University of Wisconsin Hospital and Clinics.
From 2006 to 2009 she was the president of the Health Council at the Ministry of Health of Slovenia. From 2012 to 2017, she was the President of the Educational Council at the Medical Chamber of Slovenia. Currently, she is the head of the ID Consultancy Service at UMC Ljubljana, and vice chair of the Department of Infectious Diseases. Since 2004 she is the president of the Slovenian Society of Chemotherapy and since 2005 the vice-president of the Intersectoral Coordination Mechanism for Prudent Use of Antimicrobials at the Ministry of Health. Since 2008 she is the head of the Antibiotic Committee in UMC Ljubljana. Since 2015 she is the chair of the European Society of Clinical Microbiology and Infectious diseases (ESCMID) Study group for Antibiotic policies (ESGAP). She actively participates in several European level initiatives in the field of antimicrobial resistance and stewardship.
She is full professor of infectious diseases at the Medical School, University of Ljubljana. She was the organizer and co-organizer of several international and national scientific meetings and educational courses, and the author of several national antimicrobial guidelines and handbooks on antimicrobial therapy. Her current focus of interest in research is antibiotic stewardship, infections in surgery, and infections with multiple resistant bacteria.